Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complete responses, many of which have lasted for multiple decades. More recently, a large number...

Descripción completa

Detalles Bibliográficos
Autores principales: Rini, Brian I., McDermott, David F., Hammers, Hans, Bro, William, Bukowski, Ronald M., Faba, Bernard, Faba, Jo, Figlin, Robert A., Hutson, Thomas, Jonasch, Eric, Joseph, Richard W., Leibovich, Bradley C., Olencki, Thomas, Pantuck, Allan J., Quinn, David I., Seery, Virginia, Voss, Martin H., Wood, Christopher G., Wood, Laura S., Atkins, Michael B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109802/
https://www.ncbi.nlm.nih.gov/pubmed/27891227
http://dx.doi.org/10.1186/s40425-016-0180-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109802/
https://www.ncbi.nlm.nih.gov/pubmed/27891227
http://dx.doi.org/10.1186/s40425-016-0180-7

Ejemplares similares